Free Trial

ReShape Lifesciences Q2 2024 Earnings Report

ReShape Lifesciences logo
$4.38 -0.09 (-2.01%)
(As of 12/20/2024 05:51 PM ET)

ReShape Lifesciences EPS Results

Actual EPS
-$3.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ReShape Lifesciences Revenue Results

Actual Revenue
$1.97 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ReShape Lifesciences Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

ReShape Lifesciences Earnings Headlines

ReShape Lifesciences files to sell 2.11M shares of common stock for holders
Q3 2024 ReShape Lifesciences Inc Earnings Call
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
ReShape Lifesciences Reports Q3 Growth and Strategic Moves
See More ReShape Lifesciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ReShape Lifesciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ReShape Lifesciences and other key companies, straight to your email.

About ReShape Lifesciences

ReShape Lifesciences (NASDAQ:RSLS) provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

View ReShape Lifesciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings